AUS
NZ
UK
CA
USA
IND
Highlights:
- Eli Lilly's market capitalization reaches $767 billion with a P/E ratio of 87.37.
- The company has a current ratio of 1.27 and a debt-to-equity ratio of 2.03.
- Eli Lilly's 1-year low stands at $637, with its 1-year high at $972.53.
Eli Lilly and Company is a leading entity in the healthcare and pharmaceutical sector, primarily engaged in the production and development of pharmaceutical products. The company’s stock, listed under the ticker symbol (NYSE:LLY), has exhibited considerable movement in its share price in recent months, reflecting broader market dynamics and sector-specific trends.
The market capitalization of Eli Lilly stands at approximately $767 billion, emphasizing its significant role within the pharmaceutical industry. Its price-to-earnings (P/E) ratio is marked at 87.37, offering a measure of the company's valuation in relation to its earnings. Additionally, the price-to-earnings-to-growth (P/E/G) ratio is 1.59, highlighting the connection between its market value, earnings, and growth rate.
Financially, Eli Lilly maintains a debt-to-equity ratio of 2.03, which indicates a reliance on debt for financing compared to its equity. The company's current ratio, at 1.27, suggests a moderate ability to meet short-term obligations with its current assets. Meanwhile, the quick ratio, at 0.97, demonstrates the firm’s capacity to cover short-term liabilities, excluding inventory.
The share price of Eli Lilly has fluctuated significantly over the past year, with a low of just above $600 and a high approaching $970. These price movements reflect the inherent volatility that is often seen in the pharmaceutical sector, driven by factors such as regulatory decisions, market conditions, and product developments.
Looking at the company's recent price trends, the fifty-day moving average price stands just below $780, while the two-hundred-day moving average price is slightly above $840. These moving averages help provide insights into the short-term and long-term trends in the stock’s price, with the fifty-day average capturing more immediate market sentiment and the two-hundred-day average offering a broader perspective.
Eli Lilly’s performance in the stock market continues to be a key point of interest for those monitoring developments within the pharmaceutical industry, especially as the company navigates challenges and seeks to maintain its strong market position.
